|
Greg Dane most recently served as President and Chief Executive Officer of Somatocor Pharmaceuticals, Incorporated, an early-stage private company based in Atlanta, Georgia developing a small-molecule peptidomimetic of somatostatin, targeted at inhibiting angiogenesis in retinal diseases and other microvascular diabetes complications. Prior to Somatocor, he served for two years as President and Chief Executive Officer of VitaGen Incorporated, a private, San Diego-based biotechnology company developing an extracorporeal cellular therapy for acute liver failure. Prior to joining VitaGen, from 1993 to 1999 he was President and Chief Executive Officer of Neocrin Company, a privately held biotechnology firm in Irvine, California developing an implantable cellular therapy for diabetes. From 1984 to 1993, Greg was Vice President of Research and Development and General Manager of Allergy Therapy for Baxter Healthcare Corporation in Europe. During this period he enlarged and strengthened Baxter’s European R&D operations, initiated a life sciences group, and was directly responsible for establishing a new global business initiative to develop and commercialize immunotherapies for treating allergic asthma. Prior to his position in Europe, Greg was Director of Advanced Engineering Technology for Baxter at its corporate headquarters in Deerfield, Illinois. Greg currently serves on the Board of Directors of the Georgia Biomedical Partnership, was a Director of Somatocor, a Director and member of the Executive Committee of VitaGen, a Director of Neocrin Company, and also served on the Board of Directors of the Life Sciences Industry Council in Orange County, California from 1993 to 1997. Greg received both a Bachelor of Science degree and a Masters in Engineering from Cornell University. | 